Skip to main content

Advertisement

Log in

Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer

  • Original Article
  • Published:
Tumor Biology

Abstract

Cancer-associated autoantibodies show promise as sensitive biomarkers for the early detection of cancer. To test the immunogenicity of chromogranin A (ChgA) as a B cell autoantigen and to assess the potential applications of ChgA autoantibodies as novel biomarkers for the diagnosis of non-small cell lung cancer (NSCLC), we developed a high-content peptide microarray using ChgA peptides. Autoantibody profiling was carried out using sera from 168 individuals with NSCLC and 97 healthy controls. We present evidence for the occurrence of autoantibodies to ChgA peptides in patient sera and identified five highly responsive peptides in the NSCLC group using significance analysis of microarray (SAM). Receiver operating characteristic analyses showed that ChgA autoantibodies are valuable in the predictive diagnosis of NSCLC, suggesting that serum autoantibodies to ChgA-derived peptides are promising novel markers of NSCLC. Moreover, the high-content peptide microarray antibody profiling reported in this work provides a powerful tool to visualize the overall B cell response to ChgA peptides and should enable the rapid development of in-depth research into ChgA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2014.

    Google Scholar 

  2. Berendsen HH, De Leij L, Poppema S, Postmus PE, Boes A, Sluiter HJ. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. Journal of Clinical Oncology. 1989;7(11):1614–20.

    Article  CAS  PubMed  Google Scholar 

  3. Graziano SL, Mazid R, Newman N, Tatum A, Oler A, Mortimer JA, et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. Journal of Clinical Oncology. 1989;7(10):1398–406.

    Article  CAS  PubMed  Google Scholar 

  4. Howe M, Chapman A, Kerr K, Dougal M, Anderson H, Hasleton PS. Neuroendocrine differentiation in non‐small cell lung cancer and its relation to prognosis and therapy. Histopathology. 2005;46(2):195–201.

    Article  CAS  PubMed  Google Scholar 

  5. Chiari M, Cretich M, Corti A, Damin F, Pirri G, Longhi R. Peptide microarrays for the characterization of antigenic regions of human chromogranin A. Proteomics. 2005;5(14):3600–3.

    Article  CAS  PubMed  Google Scholar 

  6. O'connor D, Frigon R. Chromogranin A, the major catecholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. Journal of Biological Chemistry. 1984;259(5):3237–47.

    PubMed  Google Scholar 

  7. Sobol RE, Memoli V, Deftos LJ. Hormone-negative, chromogranin A-positive endocrine tumors. The New England Journal of Medicine. 1989;320(7):444–7.

    Article  CAS  PubMed  Google Scholar 

  8. Nisman B, Heching N, Biran H, Barak V, Peretz T. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer. Tumor Biology. 2006;27(1):8–16.

    Article  CAS  PubMed  Google Scholar 

  9. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A—biological function and clinical utility in neuroendocrine tumor disease. Annals of Surgical Oncology. 2010;17(9):2427–43.

    Article  PubMed  Google Scholar 

  10. Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, et al. Chromogranin A is an autoantigen in type 1 diabetes. Nature Immunology. 2010;11(3):225–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Gottlieb PA, Delong T, Baker RL, Fitzgerald-Miller L, Wagner R, Cook G, et al. Chromogranin A is a T cell antigen in human type 1 diabetes. Journal of Autoimmunity. 2014;50:38–41.

    Article  CAS  PubMed  Google Scholar 

  12. Tan HT, Low J, Lim SG, Chung M. Serum autoantibodies as biomarkers for early cancer detection. FEBS Journal. 2009;276(23):6880–904.

    Article  CAS  PubMed  Google Scholar 

  13. Leidinger P, Keller A, Ludwig N, Rheinheimer S, Hamacher J, Huwer H, et al. Toward an early diagnosis of lung cancer: an autoantibody signature for squamous cell lung carcinoma. International Journal of Cancer. 2008;123(7):1631–6.

    Article  CAS  PubMed  Google Scholar 

  14. Wu L, Chang W, Zhao J, Yu Y, Tan X, Su T, et al. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clinical Cancer Research. 2010;16(14):3760–8.

    CAS  PubMed  Google Scholar 

  15. Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumor Biology. 2012;33(5):1319–26.

    Article  CAS  PubMed  Google Scholar 

  16. Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. Journal of proteome research. 2008;7(4):1388–94.

    Article  CAS  PubMed  Google Scholar 

  17. Ma H, Wu Y, Yang X, Liu X, He J, Fu L, et al. Integrated poly (dimethysiloxane) with an intrinsic nonfouling property approaching “absolute” zero background in immunoassays. Analytical chemistry. 2010;82(15):6338–42.

    Article  CAS  PubMed  Google Scholar 

  18. Larsen J, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006;2(2):1–7.

    Google Scholar 

  19. Hecker M, Lorenz P, Steinbeck F, Hong L, Riemekasten G, Li Y, et al. Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis. Autoimmunity reviews. 2012;11(3):180–90.

    Article  CAS  PubMed  Google Scholar 

  20. Corti A. Chromogranin A, and the tumor microenvironment. Cellular and molecular neurobiology. 2010;30(8):1163–70.

    Article  CAS  PubMed  Google Scholar 

  21. Lu L, Wang YN, Li MC, Wang HB, Pu LJ, Niu WQ, et al. Reduced serum levels of vasostatin-2, an anti-inflammatory peptide derived from chromogranin A, are associated with the presence and severity of coronary artery disease. European Heart Journal. 2012;33(18):2297–306.

    Article  CAS  PubMed  Google Scholar 

  22. Nikoopour E, Cheung R, Bellemore S, Krougly O, Lee‐Chan E, Stridsberg M, et al. Vasostatin‐1 antigenic epitope mapping for induction of cellular and humoral immune responses to chromogranin A autoantigen in NOD mice. European journal of immunology. 2014;44(4):1170–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This project was partially supported by: CAS Fund (KJZD-EW-J01) and JS Grants (BK20130008, BY2011180) to H.M., Jiangsu Planned Projects for Postdoctoral Research Funds (1401068C) to Y.X., and Science and Technology Planned Projects of Suzhou (SYS201329) to M.J.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Guohao Gu or Yinqiang Xin.

Additional information

Songnan Qi and Mo Huang contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

Supplemental Table 1. Sequence information of the 40 peptides of ChgA. (DOC 75 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qi, S., Huang, M., Teng, H. et al. Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer. Tumor Biol. 36, 9979–9985 (2015). https://doi.org/10.1007/s13277-015-3794-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3794-3

Keywords

Navigation